A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced ...

After definitive surgery, patients received adjuvant pembrolizumab (pembrolizumab ... Sesinando Daval-Santos IV, for collection of data, supervision of research, provision of trial materials ...

Histologic or cytologic confirmation of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy. Only if patient has had previous exposure to anti-PD-1 or anti-PD-L1 ...

Ivonescimab improved PFS when compared to pembrolizumab as first-line therapy in patients with advanced NSCLC in the phase 3 HARMONi-2 trial.

The therapeutic landscape for non–small cell lung cancer (NSCLC) has been relatively stable since the 2016 approval of ...

In the article that accompanies this editorial, 7 KEYNOTE-789, a randomized phase III trial of carboplatin- or cisplatin-pemetrexed-pembrolizumab versus carboplatin- or cisplatin-pemetrexed in 492 ...

Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug ...

Currently, BioAtla is enrolling patients in a Phase 2 study evaluating evalstotug in combination with pembrolizumab for ...